Opportunity Listing - SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)

There has been a lapse in appropriated federal funds as of October 1, 2025. Grants.gov and Simpler.Grants.gov will still be available, but service may be delayed with reduced Federal support staff presence.

For those programs affected by the funding lapse, the Grants.gov and Simpler.Grants.gov systems will accept and store applications until such time as the responsible awarding agency has the authority and funding to return to normal business operations.

This site is a work in progress, with new features and updates based on your feedback.

Search for grants here. To use more advanced features or to apply, go to Grants.gov.

SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)

Agency: National Institutes of Health

Assistance Listings: 93.394 -- Cancer Detection and Diagnosis Research

93.395 -- Cancer Treatment Research

Last Updated: April 23, 2024

View version history on Grants.gov

Description

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this NOFO is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This NOFO is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and...

third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.

Eligibility

Eligible applicants

Business

Small businesses

Additional information

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

Grantor contact information

Description

NIH Grants Information grantsinfo@nih.gov

Email

See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.

grantsinfo@nih.gov

Documents

File name	Description	Last updated
RFA-CA-24-022-Full-Announcement.html	RFA-CA-24-022 Full Announcement Text	Apr 23, 2024 05:13 PM UTC

Link to additional information

https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-022.html

Archived: September 26, 2024

Application process

This site is a work in progress. Go to www.grants.gov to apply, track application status, and subscribe to updates.

Award

$--

Program Funding

Expected awards

$--

Award Minimum

$--

Award Maximum

Funding opportunity number:

RFA-CA-24-022

Cost sharing or matching requirement:

Funding instrument type:

Grant

Opportunity Category:

Discretionary

Opportunity Category Explanation:

Category of Funding Activity:

Education

Health

Category Explanation:

History

Version:

Posted date:

April 23, 2024

Archive date:

September 26, 2024